4.7 Article

Structure-Activity Relationship and Mechanism of Action Studies of Manzamine Analogues for the Control of Neuroinflammation and Cerebral Infections

期刊

JOURNAL OF MEDICINAL CHEMISTRY
卷 53, 期 1, 页码 61-76

出版社

AMER CHEMICAL SOC
DOI: 10.1021/jm900672t

关键词

-

资金

  1. National Institutes of Health [1R01A136596, 5K02A-101502]
  2. NIAID
  3. Division of AIDS [AI 27094]
  4. USDA Agricultural Research Service Specific Cooperative [58-6408-2-0009]
  5. Midwestern University
  6. National Science Foundation [EPS-0556308]
  7. Centers for Disease Control and Prevention National Center for Zoonotic, Vector-Borne, and Enteric Diseases (NCZVED)
  8. American Association of Colleges of Pharmacy New Investigator
  9. NIH National Center for Research Resources (NCRR) [P20 RR021929, C06 RR-14503-01]
  10. University of Mississippi's Office of Research and Sponsored Programs, Partners and Provost's Associates
  11. CORE-NPN Natural Products Neuroscience
  12. EPSCoR
  13. Office Of The Director [903787] Funding Source: National Science Foundation

向作者/读者索取更多资源

Structure-activity relationship Studies were carried Out by chemical modification of manzamine A (1), 8-hydroxymanzamine A (2), manzamine F (14), and ircinal isolated from the sponge Acanthostrongy-lophora. The derived analogues were evaluated for antimalarial, antimicrobial, and antineuroinflammatory activities. Several modified products exhibited potent and improved in vitro antineuroinflammatory, antimicrobial, and antimalarial activity. I showed improved activity against malaria compared to chloroquine in both multi- and single-dose in vivo experiments. The significant antimalarial potential was revealed by a 100% cure rate of malaria in mice with one administration of 100 mg/kg of 1. The potent antineuroinflammatory activity of the manzamines will provide great benefit for the prevention and treatment of cerebral infections (e.g., Cryptococcus and Plasmodium). In addition, I was shown to permeate across the blood-brain barrier (BBB) in an in vitro model using a MDR-MDCK monolayer. Docking Studies Support that 2 binds to the ATP-noncompetitive pocket of glycogen synthesis kinase-3 beta (GSK-3 beta), which is a putative target of manzamines. On the basis of the results presented here, it will be possible to initiate rational drug design efforts around this natural product scaffold for the treatment of several different diseases.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据